Особенности формотерола в препарате "Оксис Турбухалер"
- Авторы: Княжеская Н.П1
-
Учреждения:
- ГОУ ВПО РГМУ Росздрава, Москва
- Выпуск: Том 8, № 10 (2006)
- Страницы: 62-65
- Раздел: Статьи
- URL: https://journal-vniispk.ru/2075-1753/article/view/92246
- ID: 92246
Цитировать
Полный текст
Аннотация
В последнее время довольно остро стоит вопрос о широком применении b2-агонистов длительного действия. Это прежде всего связано с желанием врачей назначать наиболее эффективные препараты с высоким профилем безопасности.На сегодняшний день формотерол является самым оптимальным и универсальным бронхорасширяющим препаратом с высоким профилем безопасности и выраженным бронхопротективным эффектом. Следует еще раз подчеркнуть, что формотерол применяется только в сочетании с адекватными дозами ингаляционных глюкокортикостероидов (ИГКС).
Ключевые слова
Полный текст
Открыть статью на сайте журналаСписок литературы
- Глобальная стратегия лечения и профилактики бронхиальной астмы. Под ред. академика РАМН А.Г.Чучалина. М.: Атмосфера, 2002.
- Aalbers R, Backer V, Kava T.T.K et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed - dose salmeterol/fluticasone in moderate to severe asthma. Current Med Research Opinion 2004; 20 (2): 225–40.
- Ankerst J, Persson G, Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients. Eur Respir J 2000; 16 (Suppl. 31): 33s+poster.
- Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sci 1993; 52: 2145–60.
- Barnes P.J. Clinical outcome of adding long - acting b - agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl. B): S12–S16.
- Barnes P.J. Scientific rationale for inhaled combination therapy with long - acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
- Buhl R, Kardos P, Richter K et al. The effect of adjustable dosing with budesonide/formoterol on health - related quality of life and asthma control compared with fixed dosing. Current Med Research Opinion 2004; 20 (8): 1209–20.
- Canonica G.W, Castellani P, Cazzola M et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulmon Pharmacol Ther 2004; 17 (4): 239–47.
- Crisholm S et al. Once - daily budesonide in mild asthma. Respir Med 1998; 421–5.
- Foresi A, Morelli M.C, Catena E. Low - dose budesonide with the addition of an increased dose during exacerbations is effective in long - term asthma control. Chest 2000; 117: 440–6.
- http://www.fda.gov/
- Kips J.C, O'Connor B.J, Inman M.D. A long - term study of the anti - inflammatory effects of low - dose budesonide plus formoterol versus high - dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996–1001.
- Mak J.C.W, Nishikawa M, Barnes P.J. Glucocorticoids increase b2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268: L41–6.
- Mak J.C.W, Nishikawa M, Shirasaki H et al. Protective effects of a glucocorticoid on downregulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99–106.
- Miller-Larsson A, Mattsson H, Hjertberg E et al. Reversible fatty acid conjugation of budesonide: novel mechanism foe prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26: 623-30
- Miller-Larsson A et al. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000; 162: 1455–61.
- Molimard M et al. Long - and short - adrenoreceptor agonists: interactions in human contracted bronchi. Eur Respir J 1998; 11: 583–8.
- Nials A.T, Ball D.I, Butchers P.R et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251: 127–35.
- O'Byrne P.M, Barnes P.J, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomised trial. Am J Respir Crit Care Med 2001; 164: 1392–7.
- O,Connor B.J, Alkinan S.L, Barnes P.J. Tolerance to the non - bronchodilatator effects of inhaled b2-agonists in asthma. N Engl J Med 1992; 327: 1204–8.
- Palmquist M et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244–9.
- Pauwels R.A, Sears N.R,Cambell M et al. Formoterol as relie medication in asthma: a world safety and effectiveness trial. Eur Respir J 2003; 22: 787–94.
- Pauwels R.A, Lofdahl C.G, Postma D.S et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol And Corticosteroids Establishing Therapy (FACET) International Study Group. N Eng J Med 1997; 337: 1405–11.
- Politiek M.J, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine - induced severe bronchoconstriction. Eur Respir J 1999; 13: 988–92.
- Stallberg B, Olsson P, Jorgensen L.A et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Internat J Clin Pract 2003; 57 (8): 656–61.
- Tattersfield A.E, Lofdahl C-G, Postma D.S et al. Comparison of formoterol and terbutaline for as - needed treatment of asthma: a randomised controlled trial. Lancet 2001; 357: 257–61.
- van Noord J.A, Smeets J.J, Raaijmakers J.A et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684–8.
Дополнительные файлы
